Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Analysts

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $24.50.

A number of research firms have recently commented on KURA. Barclays cut their price objective on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Friday, June 20th. Mizuho cut their price objective on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, May 19th. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Finally, JMP Securities restated a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Wednesday, June 4th.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of KURA. Rhumbline Advisers raised its holdings in shares of Kura Oncology by 2.0% during the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after buying an additional 1,923 shares during the period. US Bancorp DE raised its holdings in shares of Kura Oncology by 184.5% during the 4th quarter. US Bancorp DE now owns 22,104 shares of the company's stock valued at $193,000 after buying an additional 14,335 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Kura Oncology by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company's stock valued at $5,535,000 after purchasing an additional 10,542 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology during the 4th quarter valued at approximately $90,000. Finally, AlphaQuest LLC acquired a new stake in Kura Oncology during the 4th quarter valued at approximately $177,000.

Kura Oncology Trading Down 1.2%

NASDAQ KURA traded down $0.07 during trading hours on Monday, hitting $5.73. 817,786 shares of the company's stock were exchanged, compared to its average volume of 1,240,013. The business's 50 day moving average is $6.18 and its 200-day moving average is $7.21. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $23.48. The firm has a market capitalization of $496.05 million, a P/E ratio of -2.73 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to analysts' expectations of $39.08 million. As a group, analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.